 |
answer text |
<p>The Department has not discussed with the National Institute for Health and Care
Excellence (NICE) the prescription of medicinal cannabis oil for patients with cerebral
palsy and arthritis.</p><p> </p><p>NICE is the independent expert body that develops
authoritative, evidence-based guidance for the National Health Service on whether
drugs and other treatments represent a clinically and cost effective use of NHS resources.
NICE is developing guidance on the prescribing of cannabis-based medicinal products
by October 2019. It will be based on the best available international evidence and
will have been produced using NICE’s world-renowned process for delivering such guidance.</p><p>
</p><p>Following a public consultation on the draft scope, the guidance will focus
on the use of cannabis-based products in the treatment of chronic pain, intractable
nausea and vomiting, spasticity and severe treatment-resistant epilepsy, conditions
where the evidence is currently most advanced. A consultation on the draft guidance
is expected in the summer.</p>
|
|
